The NCMAG Council makes decisions on the proposed use of cancer medicines.
These medicines uses are planned for review by NCMAG:
| Medicine | Use | Council meeting date | Planned publication date | ID number |
|---|---|---|---|---|
| Medicine Anastrozole | Use The primary prevention of breast cancer in post-menopausal women at moderate to high risk. (on-label and off-patent use) | Council meeting date To be confirmed | Planned publication date To be confirmed | ID number NCMAG113 |
| Medicine Raloxifene | Use The primary prevention of breast cancer in post-menopausal women at moderate to high risk whom anastrozole is unsuitable. (off-label use and off-patent medicine) | Council meeting date To be confirmed | Planned publication date To be confirmed | ID number NCMAG114 |
| Medicine Tamoxifen | Use The primary prevention of breast cancer in women at moderate or high risk. (on-label use and off-patent medicine) | Council meeting date To be confirmed | Planned publication date To be confirmed | ID number NCMAG115 |
| Medicine Dasatinib | Use For the treatment of adult patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukaemia resistant or intolerant to prior therapy, including imatinib. (on-label use and off-patent medicine) | Council meeting date 20 June 2024 | Planned publication date 25 July 2024 | ID number NCMAG116 |
| Medicine Dasatinib | Use For the treatment of adult patients with newly diagnosed Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukaemia. (Off-label use and off-patent medicine) | Council meeting date 20 June 2024 | Planned publication date 25 July 2024 | ID number NCMAG117 |